IKA 2024: Pediatric prevalence of keratoconus and the dire clinical implications

News
Video

Early diagnosis of keratoconus is vital given the disease's prevalence in pediatric patient, according to Jennifer Harthan, OD, FAAO, FSLS.

Jennifer Harthan, OD, FAAO, FSLS, shared the importance of early diagnostics and pediatric screening of keratoconus as discussed in a talk she gave with Andrew S. Morgenstern, FAAO, FNAP; S. Barry Eiden, OD, FAAO, FSLS; and Ann Ostrovsky, MD during this year's International Keratoconus Academy (IKA) Keratoconus Symposium.

Video Transcript

Editor’s note - The following transcript has been lightly edited for clarity.

Jennifer Harthan, OD, FAAO, FSLS:

Hi, my name is Jen Harthan. I'm Chief of the Cornea and Contact Lens Clinic at the Illinois College of Optometry and I'm here at the IKA meeting. I was able to present our research on pediatric prevalence yesterday and key takeaways from the meeting are that pediatric prevalence of keratoconus is higher than we had previously thought. And it's in line with recent reports of the adult prevalence of keratoconus. So, what does that mean for us? What it means is that we should be looking for it. We need early diagnostics to screen for pediatric keratoconus in our offices and we also need to be treating at [inaudible], a time of diagnosis. So, as we know, when patients are diagnosed with keratoconus earlier, they tend to have worse prognosis and their disease tends to be much more complex, more complicated, and many of those patients often need a corneal transplant down the road. So if we can diagnose them earlier, we can actually treat them earlier with the new treatments maybe that we're hearing and then also they have better quality of life down the road which is think in our world that's ultimately our goal is to improve their quality of life and to prevent vision loss.

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Karl Stonecipher ASCRS 2025
AnnMarie Hipsley, DPT, PhD, at ASCRS 2025
Neda Shamie, MD; Selina McGee, OD, FAAO, Dipl ABO; and Jacob Lang, OD, FAAO; provided their insights during CIME 2025 on May 4.
At ARVO 2025, Mark Bullimore, MCOptom, PhD, emphasized the need for more accurate, condition-specific tools in evaluating myopic eye growth and treatment efficacy.
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Neda Shamie, MD, speaks on cataract and refractive surgery at CIME 2025.
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
© 2025 MJH Life Sciences

All rights reserved.